STOCK TITAN

Morphic Announces Participation In Cowen 42nd Annual Healthcare Conference

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Morphic Therapeutic (Nasdaq: MORF) announced that its President and CEO, Praveen Tipirneni, M.D., will participate in a virtual panel on gastrointestinal and microbiome topics at the 42nd Annual Cowen Healthcare Conference on March 9th at 10:30 AM ET. The event will be accessible via live webcast on the company's investor website, with a replay available afterward. Morphic is focused on developing oral integrin therapies for serious chronic diseases, partnering with AbbVie, Janssen, and Schrödinger, and utilizing its proprietary MInT technology platform.

Positive
  • Participation in a prominent healthcare conference enhances visibility.
  • Collaboration with established companies like AbbVie and Janssen supports credibility.
  • Focus on developing therapies for serious chronic diseases indicates strong market potential.
Negative
  • None.

WALTHAM, Mass., March 04, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced Morphic President and CEO Praveen Tipirneni, M.D. will participate in a gastrointestinal and microbiome virtual panel discussion at the 42nd Annual Cowen Healthcare Conference at 10:30 AM ET on Wednesday, March 9th.

A live webcast of the event will be available on the Investor section of Morphic’s website at www.morphictx.com. An archived replay will be available on the company’s website following the conference.

About Morphic Therapeutic

Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis and cancer. In collaboration with AbbVie, Janssen, and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.

Contacts
Morphic Therapeutic
Chris Erdman
chris.erdman@morphictx.com
617.686.1718


FAQ

What event will Morphic Therapeutic's CEO participate in?

Morphic Therapeutic's CEO will participate in the 42nd Annual Cowen Healthcare Conference on March 9th.

What is the focus of Morphic Therapeutic's development efforts?

Morphic Therapeutic is developing oral integrin therapies for the treatment of serious chronic diseases.

Where can I watch the live webcast of the Morphic Therapeutic panel discussion?

The live webcast can be accessed on Morphic Therapeutic's investor website.

When will the replay of the Morphic Therapeutic panel discussion be available?

An archived replay will be available on the company's website following the conference.

Who is collaborating with Morphic Therapeutic?

Morphic Therapeutic collaborates with AbbVie, Janssen, and Schrödinger in its development efforts.

Morphic Holding, Inc.

NASDAQ:MORF

MORF Rankings

MORF Latest News

MORF Stock Data

2.86B
40.99M
17.13%
91.02%
3.78%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WALTHAM